Early Phase Trials Unit, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France; Department of Medicine, Institut Bergonié, 229 Cours de l'Argonne, 33000 Bordeaux, France.
INSERM U1035, ATIP-AVENIR, Université de Bordeaux, Bordeaux, France; Department of Dermatology and Paediatric Dermatology, National Centre for Rare Skin disorders, Saint-André and Pellegrin Hospital, Bordeaux, France.
Pharmacol Ther. 2018 Jan;181:91-100. doi: 10.1016/j.pharmthera.2017.07.005. Epub 2017 Jul 15.
Immunotherapies are changing the landscape of advanced solid tumor treatment. These therapies have different mechanisms of action and include oncolytic viruses, checkpoint inhibitors, such as CTLA-4 or PD1/PD-L1 monoclonal antibodies, and CSF-1R antibodies. Given the growing therapeutic impact of these agents in oncology, it is important to better understand their properties. Immunotherapies generate new toxicity profiles that are called immune-related adverse events and require specific management. This review focuses on the mechanisms of action of such side effects, as well as their description and their general management.
免疫疗法正在改变晚期实体瘤治疗的格局。这些疗法具有不同的作用机制，包括溶瘤病毒、检查点抑制剂，如 CTLA-4 或 PD1/PD-L1 单克隆抗体，以及 CSF-1R 抗体。鉴于这些药物在肿瘤学中的治疗作用不断增加，更好地了解它们的特性非常重要。免疫疗法产生了新的毒性谱，称为免疫相关不良事件，需要进行专门的管理。本文重点介绍这些副作用的作用机制，以及它们的描述和一般管理。
